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A B S T R A C T
Background
Acute traumatic brain injury is a major cause of death and disability. Calcium channel blockers (calcium antagonists) have been used
in an attempt to prevent cerebral vasospasm after injury, maintain blood flow to the brain, and so prevent further damage.
Objectives
To estimate the effects of calcium channel blockers in patients with acute traumatic brain injury, and in a subgroup of brain injury
patients with traumatic subarachnoid haemorrhage.
Search methods
We searched the Cochrane Injuries Group’s Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE,
EMBASE and the reference lists of relevant articles. We also contacted experts in the field. The searches were updated in November
2005.
Selection criteria
Randomised controlled trials (RCTs) in patients with all levels of severity of clinically diagnosed acute traumatic brain injury.
Data collection and analysis
Two authors independently assessed the identified studies for eligibility and extracted data from each study. Summary odds ratios were
calculated using the Mantel-Haenszel method.
Main results
Six RCTs involving 1862 participants were included. The effect of calcium channel blockers on the risk of death was reported in five
of the RCTs. The pooled odds ratio (OR) for the five studies was 0.91 (95% confidence interval [95% CI] 0.70 to 1.16). For the five
RCTs that reported death and severe disability (unfavourable outcome), the pooled OR 0.97 (95%CI 0.81 to 1.18). In the two RCTs
which reported the risk of death in a subgroup of traumatic subarachnoid haemorrhage patients, the pooled OR 0.59 (95% CI 0.37
to 0.94). Three RCTs reported death and severe disability as an outcome in this subgroup, and the pooled OR 0.67 (95% CI 0.46 to
0.98).
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Authors’ conclusions
This systematic review of randomised controlled trials of calcium channel blockers in acute traumatic head injury patients shows that
considerable uncertainty remains over their effects. The effect of nimodipine in a subgroup of brain injury patients with subarachnoid
haemorrhage shows a beneficial effect, though the increase in adverse reactions suffered by the intervention group may mean that the
drug is harmful for some patients.
P L A I N L A N G U A G E S U M M A R Y
Does a group of drugs known as calcium channel blockers reduce mortality and unfavourable complications in patients with
traumatic brain injury?
Acute traumatic brain injury is a major cause of death and disability. Not all damage to the brain occurs at the moment of injury;
reduction of blood flow and oxygen supply to the brain can occur afterwards and cause further brain damage, which is an important
cause of avoidable death and disability. In the early stages after injury it is therefore important that efforts are made to minimise
secondary brain damage and to provide the best chances of recovery from established brain damage.
The use of calcium channel blockers has been proposed for the prevention or treatment of cerebral vasospasm (that is, sudden narrowing
of blood vessels in the brain), which can occur after brain injury and cause secondary brain damage due to a reduction in blood flow.
It is important to determine whether or not calcium channel blockers might be effective in reducing mortality and unfavourable
outcomes in head-injured patients.
This review looked at all high quality trials comparing the use of calcium channel blockers with a control, in head-injured patients of
any age. The authors also looked at trials involving patients suffering from subarachnoid haemorrhage (that is, bleeding into the space
between the brain and the skull) caused by an injury, as a subgroup.
The authors found six eligible trials involving 1862 patients. The results indicate that there is insufficient evidence to support the use of
calcium channel blockers. The authors conclude that there is some evidence that a calcium channel blocker called nimodipine may be
beneficial for some patients with subarachnoid haemorrhage. However, there is also an indication of certain adverse reactions amongst
patients treated with nimodipine which may mean that the drug is harmful for some individuals.
The authors recommend that the promising results in patients with subarachnoid haemorrhage are replicated in a larger well designed
trial, before any firm conclusions about the effectiveness of the drug can be drawn. In future trials, data on outcomes other than death
and severe disability, such as quality of life of the survivors and the economic utility of the drug, should be measured; such outcomes
have not been considered in existing research.
B A C K G R O U N D
Acute traumatic brain injury is a major cause of death and dis-
ability (Jennett 1977) and has been defined as “an acquired injury
to the brain caused by an external physical force, resulting in to-
tal or partial disability or impairment” (Moscato 1994). Not all
damage to the brain occurs at the moment of impact. Reduction
of blood flow and oxygen supply to the brain can occur and cause
secondary brain damage, which is an important cause of avoid-
able death and disability (Gentleman 1990). For most secondary
events after head injury, the final common path is a critical reduc-
tion in cerebral blood flow, leading to loss of cellular integrity and
ischaemic neuronal damage (Matthews 1995).
The management of acute traumatic brain injury is thought to be
of critical importance in determining the eventual outcome. The
aim in the early stages is to minimise the secondary brain damage
and to provide the best chances of recovery from established brain
damage. In the later stages, the aim is to improve the functional
health of the patient (Sharples 1995).
Calcium channel blockers (also known as calcium antagonists) re-
duce the influx of calcium into the cell by blocking the calcium
channels. Their use has been suggested for prevention or treatment
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of cerebral vasospasm after acute traumatic brain injury, based on
the hypothesis that these drugs can counteract the influx of extra-
cellular calcium in the vascular smooth-muscle cells and prevent
the blood vessels constricting (Graham 1989). It is important to
determine whether or not calcium channel blockers might reduce
the incidence of ischaemia in head-injured patients.
Why it is important to do this review
The evidence for the use of calcium channel blockers is uncon-
vincing, and the known side-effects of the drugs (induced hy-
potension, cerebral vasodilatation, and impaired cerebrovascular
reactivity) may outweigh the benefits. Hence, the primary motiva-
tion and rationale for this review is to assess the available evidence
from randomised controlled trials, to estimate better the effects of
calcium channel blockers in patients with acute traumatic brain
injury and in a subgroup of traumatic subarachnoid haemorrhage
patients (tSAH).
O B J E C T I V E S
Objective 1
To estimate the effect of calcium channel blockers in head-injured
patients. The primary outcome measures are, first, total mortality
and, second, an unfavourable outcome − defined as death, severe
disability or persistent vegetative state as described by the Glasgow
Outcome Scale (Jennett 1975). Secondary outcome measures are
listed under “Types of outcome measure”.
Objective 2
To estimate the effects of calcium channel blockers as a function
of the following variables:
• time between injury and admission to hospital and the
administration of treatment;
• method of administration;
• dosage;
• age of the patient;
• type of calcium channel blocker;
• severity of the brain damage;
• duration of treatment;
• adverse side-effects of the treatment (for example,
hypotension).
Objective 3
To estimate the effects of calcium channel blockers in a subgroup
of brain injury patients with tSAH.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Patients with clinically diagnosed acute traumatic brain injury, of
any age and in any healthcare setting.
Patients with traumatic subarachnoid haemorrhage were included,
but patients with spontaneous subarachnoid haemorrhage were
excluded.
Types of interventions
Any calcium channel blocker (calcium antagonist), namely: vera-
pamil, nifedipine, nicardipine, amlodipine, felodipine, isradipine,
Iacidipine, nimodipine and diltiazem, administered in any dose,
by any route, for any duration, and at any time of onset.
Types of outcome measures
Primary outcomes
The primary outcome measures are:
• total mortality;
• an unfavourable outcome - defined as death, severe
disability or persistent vegetative state as described by the
Glasgow Outcome Scale (Jennett 1975). A favourable outcome is
usually defined as good recovery (for example, return to work) or
moderate disability.
Secondary outcomes
Other outcomes for which data were also sought were:
• quality of life;
• personality changes in adults;
• disruption to family;
• delayed development in children (for example, speech
development);
• physiological/biological measures (computerized axial
tomography (CAT) scans, cerebral blood flow);
• economic factors.
In addition, adverse side-effects of the treatment (for example,
hypotension) were studied.
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Search methods for identification of studies
The aim was to undertake a comprehensive search for all relevant
RCTs, in order to avoid bias resulting from the exclusion of any
studies.
The search was not restricted by language, publication status or
publication date.
Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group’s Specialised Register (up to
November 2005);
• Cochrane Central Register of Controlled Trials (The
Cochrane Library, issue 4, 2005);
• MEDLINE (1966 to November 2005);
• EMBASE (1988 to November 2005);
• Intensive Care National Audit & Research Centre’s
(ICNARC) database of RCTs (contains the results of the hand
searching of 33 selected journals relevant to intensive care and
emergency medicine);
• Ottawa Stroke Trials Registry.
The searches were based on the search strategy shown in Appendix
1, modified as appropriate to the specifications of each database.
Searching other resources
We searched reference lists of pertinent articles for eligible RCTs.
In addition, we asked experts active in the field and drug com-
panies who manufacture calcium channel blockers if there were
other studies, published or otherwise, that might be eligible for
inclusion.
Data collection and analysis
The authors were supported by a steering group. In advance of
collating and reviewing the relevant literature, a meeting was held
between the authors of the review and members of the steering
group to decide on the inclusion criteria for the studies and the
methods of identifying these studies. A further meeting was held
once the studies had been identified and quality assessed to discuss
the results of the literature search and propose a plan for analysis.
Finally, once the analysis was completed, a meeting was held to
discuss the results and possible implications.
Selection of studies
One author scanned all abstracts of all studies identified through
electronic searching and retrieved the full text of relevant articles.
Two authors (JL and CG) independently assessed the identified
studies for eligibility. Any disagreements were discussed with a
third review author (KR) until agreement was reached.
Data extraction and management
We extracted the following data from each study:
• the number of participants randomised to each group;
• inclusion and exclusion criteria;
• interventions;
• outcomes measured;
• number of participants lost to follow-up;
• summary of the results.
Assessment of risk of bias in included studies
An assessment of the methodological quality of each trial report
was carried out using two validated scales (Downs 1996; Jadad
1996). Two authors (JL and CG) independently carried out this
assessment. Any disagreements were discussed with a third author
(KR) until consensus was reached.
The first scale (Jadad 1996) is designed to measure the likelihood
of bias in RCTs, based on three items: randomisation, double-
blinding, and withdrawals or drop outs after randomisation. This
scale assesses validity with three questions with a highest score
attainable of five. A second quality assessment scale was used to
assess the trials, with a highest score obtainable of 32 (Downs
1996), in order to find a greater differentiation of quality between
the four trials, not provided with Jadad 1996.
Data synthesis
Summary odds ratios were calculated in RevMan software, using
the Mantel-Haenszel method.
R E S U L T S
Description of studies
See: Characteristics of included studies.
After a full text review seven trials (Compton 1990; HIT I 1990;
HIT II 1994; HIT III 1996; HIT IV; Sahuquillo 2000; Sinha
2002) were judged to meet the inclusion criteria. Two of these
were unpublished reports (HIT IV; Sinha 2002). We wrote to the
principal investigators of these two studies for information. Data
for HIT IV were not made available by the principal investigators
of this trial but were, nevertheless, accessible to us, as they had been
presented publicly at a conference. The author of Sinha 2002 has
not responded, despite repeat letters, and we have found no other
way of accessing the data for the 50 participants in this nimodipine
study.
Contact with experts in the area and pharmaceutical companies
did not identify any additional trials, although out of the six letters
sent out to experts, and four to pharmaceutical companies only
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two replies were received (one expert, Professor Braakman and one
drug company, Roche Pharmaceuticals) Bayer and Baker Norton
did not respond.
This review is therefore based on six RCTS comprising a total of
1862 participants.
The combined search strategies identified nine reports of studies
that satisfied the inclusion criteria, relating to four eligible RCTs
that comprised 1315 randomised participants.
Details for each study are presented in the table ’Characteristics of
included studies’.
Risk of bias in included studies
We assessed the quality of RCTs using the Jadad scale, the scores
were:
Compton 1990 (5/5);
HIT I 1990 (5/5);
HIT II 1994 (2/5);
HIT III 1996 (3/5);
HIT IV (unable to assess as results not published);
Sahuquillo 2000 (3/5).
The scores on the Downs scale were:
Compton 1990 (27/32);
HIT I 1990 (22/32);
HIT II 1994 (15/32);
HIT III 1996 (18/32);
HIT IV (unable to assess as results not published);
Sahuquillo 2000 (23/32).
There was good agreement between the two scales, Compton
1990 scored highest on both scales, followed by HIT I 1990.
The reports of HIT II 1994 and HIT III 1996, however, were
of lower quality. Both scored poorly on reporting of sample size
calculations, masking and presentation of statistics.
Effects of interventions
Objective 1
Five RCTs provided data for the primary objective to estimate
the effects of calcium channel blockers on the risk of death (total
mortality): Compton 1990; HIT I 1990; HIT II 1994; HIT III
1996; Sahuquillo 2000. There were slightly fewer deaths in the
treatment group 23.2% versus 25.0%, but the difference was not
statistically significant: summary odds ratio 0.91 (95% CI 0.70
to 1.16). Exclusion of the nicardipine trials (Compton 1990 and
Sahuquillo 2000) made no difference to the result.
The four nimodipine trials (HIT I 1990; HIT II 1994; HIT III
1996; HIT IV) and Sahuquillo 2000 (nicardipine trial) also pro-
vide data to assess the effect of calcium channel blockers on an
unfavourable outcome (mortality, severe disability and persistent
vegetative state). Again, the occurrence of an unfavourable out-
come is only marginally less in the treatment group, 38.9% ver-
sus 39.1%, and this did not reach statistical significance: sum-
mary odds ratio 0.97 (95% CI 0.81 to 1.18). Again, excluding the
nicardipine trial made no difference.
No information was available to consider any of the other out-
comes.
Objective 2
Data on adverse events or side-effects (e.g. hypotension, increase
in pancreatic and liver enzymes) occurring during the trial were
available in three of the trials (HIT I 1990; HIT II 1994; HIT
III 1996). The occurrence of an adverse event is greater in the
treatment (nimodipine) group, 21.1% versus 19.1%, though this
difference is not statistically significant: summary odds ratio 1.15
(95% CI 0.87 to 1.52).
However, the number of participants suffering from hypotension
in the treatment group (nimodipine) was significantly greater than
the controls, 12.0% versus 7.4%: summary odds ratio 1.74 (95%
CI 1.20 to 2.52). No information was available to estimate the
effects of calcium channel blockers in subgroups defined by dose,
age, severity etc.
Objective 3
Information was available in two of the trials (HIT II 1994; HIT
III 1996) for estimating the effects of calcium channel blockers in a
subgroup of tSAH patients on total mortality. Fewer deaths occur
in the treatment group, 26.9% versus 38.9%. This difference does
reach statistical significance: summary odds ratio 0.59 (95% CI
0.37 to 0.94).
Informationwas available in three of the trials (HIT I 1990;HIT II
1994; HIT III 1996) for estimating the effects of calcium channel
blockers in a subgroup tSAHpatients on total mortality and severe
disability. Fewer unfavourable outcomes occur in the treatment
(nimodipine) group, 48.2% versus 57.9%. Again, this does reach
statistical significance: summary odds ratio 0.67 (95% CI 0.46 to
0.98).
D I S C U S S I O N
Objective 1
This systematic review of randomised controlled trials of calcium
channel blockers in head injury patients shows that considerable
uncertainty remains over their clinical effects. Current data make
it improbable that nimodipine has a marked beneficial or harmful
effect in unselected head injury patients.
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Objective 2
There is a significant increase in hypotension in the nimodipine
group, which may mean that the drug negates its potential bene-
ficial effects in some patients. In addition, since the trials studied
were small, there could be other adverse reactions that were not
experienced by any of the patients studied.
Objective 3
The effect of nimodipine in a subgroup of brain injury patients
with subarachnoid haemorrhage shows a clearer beneficial effect.
There is a significant increase in favourable outcome in the treat-
ment group in this subgroup of patients. However caution should
be taken over inferring too much from this result, as the quality
assessment of the reporting of showed, the quality of this study
is unclear and it contributes a large proportion of the sample size
(121 out of a sample of 460).
Not surprisingly, when the data were analysed again for the total
population excluding those with tSAH the moderate beneficial ef-
fect seen in the analysis of all patients disappears. For the outcome
total mortality the summary odds ratio was 0.91 (95% CI 0.71
to 1.17) for all patients together compared to 1.17 (95% CI 0.86
to 1.60) after exclusion of the tSAH patients. For the outcome
mortality and severe disability the summary odds ratio was 0.85
(95% CI 0.68 to 1.07) for all patients together, compared to 1.02
(95% CI 0.77 to 1.36) excluding tSAH patients.
Quality assessment of RCTs
As is often the case, we found that the quality of reporting of some
of the RCTs was below the standard needed in order to make a
true assessment of the validity of the trial (Altman 1990). Poor
reporting does not, of course, constitute a poor trial, though there
is evidence to suggest that this might be the case (Schulz 1995).
Since the quality of these trials was assessed only from the written
papers, if the quality of reporting was poor, then the score for
quality assessment will be poor.
A number of points should be stressed here. First, no attempt was
made to discuss the quality of each trial with the principal investi-
gators. Second, the purpose of assessing the quality of RCTs before
inclusion into a review is to exclude those trials whose quality is
found to be below a certain standard and therefore to reduce the
potential for bias in the results; no trialswere excluded on this basis.
Third, the quality assessment score was not used to weight RCTs
used in the meta-analysis. In view of this, it may be important to
communicate with all investigators regarding the actual procedure
of the trial in order better to assess its quality. For example in trials
where there is not adequate allocation concealment, trials are more
likely to over estimate the effect size. This is a common fault and
may not be easily assessed from the written report (Schulz 1995).
It may also be important to discuss what definitions in each trial
were used, for example, the definitions of adverse events and sever-
ity of pathology differ from trial to trial. Therefore, it may be use-
ful to obtain the original protocols for each trial to determine how
data were collected and variables defined. Preliminary enquiries
have beenmade to principal investigators of each trial and to Bayer
Pharmaceuticals (who funded HIT I, II, III and IV) regarding the
possibility of obtaining the original data, in order to conduct an
individual patient data pooled analysis. Professor Teasdale (HIT
I 1990) and Professor Braakman (HIT II 1994) have provided
informal verbal permission for use of the data, and further efforts
are underway to contact Harders (HIT III 1996) and Compton
(Compton 1990). Permission is still being sought fromBayer, who
have so far not responded, despite two letters.
The risk of bias figures are presented in Figure 1 and Figure 2.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
6Calcium channel blockers for acute traumatic brain injury (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to support the use of calciumchannel
blockers in an unselected group of patients with traumatic head
injury, although a clinically significant benefit cannot be ruled out
with the data available.
There is some evidence to suggest that nimodipine may be of
benefit to a subgroup of patients with tSAH.
Implications for research
The promising results in tSAH patients need to be replicated in a
larger RCT, before any firm conclusions about the effectiveness of
the drug can be drawn.
The outcomes to consider should include not only outcomes of
death and severe disability, but also the quality of life of the sur-
vivors and the economic utility of the drug. These are issues that
have not been addressed in the trials to date.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Compton 1990
Methods Patients n=31
Treatment n=20
Placebo n=11
Participants Inclusion
• Severe head Injury <8 Glasgow coma score, or making a flexor response, or response to pain following
initial resuscitation)
• DFV>100cm/s on 2 consecutive readings
• after 6 hours
• >10 years old
• >40kg body weight
Exclusions
• pregnant
• suffering from heart, renal or liver failure
Interventions • Nicardipine vs placebo
• 1mg/ml, in isotonic buffer, Syntex Research
• Placebo (sorbitol and vehicle)
• initially at 2.5ml/h increase to 7.5ml/h after 4 h if no response
• IV infusion
• continued for 24 hours
Outcomes • Glasgow outcome scale at discharge
• GOS at 3 months
• Doppler flow velocity
Notes • Increased favourable outcome in Nicardipine group (on DFV)
• RR = 2.67 95% CI 1.08 to 6.60
Losses to follow-up
• 1 no data, and
• 6 lost to follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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HIT I 1990
Methods Patients n=351
Treatment n=176
Placebo n=175
Participants Inclusion
• Severe head injury patients, not obeying simple commands
• <24 hours of injury
• Adults (16-70 years)
• 6 European Neurosurgical units
Exclusions
• haemodynamic instability
• clinically brain dead
• pregnant
• renal
• hepatic pulmonary or cardiac decompensation
Interventions • Nimodipine vs placebo
• dosage: 1mg initially to 2mg per hour if blood pressure did not decline
• IV
• <24 hours of injury
• up to 7 days
Outcomes • Glasgow outcome scale
• follow-up 6 months
Notes • Increased favourable outcome in Nimodipine group
• RR= 1.075; 95% CI 0.88 to 1.32
• 2 excluded from analysis
• 14 withdrawn from treatment
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
HIT II 1994
Methods Patients n=852
Treatment n=423
Placebo n=429
Participants Inclusion
• head injured, of obeying commands at time of entry (within 12 hours of patient not obeying commands)
undergone CT
• <24 hours since head injury.
• 16-70 years
• 21 Neurosurgical centres in 13 European countries
Exclusions
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HIT II 1994 (Continued)
responses could not be assessed due to previous treatment, gunshot wounds, haemodynamic instability,
pregnant, wide non reacting pupils and motor response absent for >2 hours, likely to die within 24 hours,
unlikely to be available for follow up at 6 months
Interventions • Nimodipine vs placebo
• initially 1mg/hour, increased to 2mg/hour after 2 hours
• IV
• for 7 days or death of patient.
Outcomes • Glasgow outcome scale
• 6 months
Notes • increased favourable outcome in Nimodipine group
• RR = 1.02; 95% CI 0.91 to 1.14
• 33 lost to follow up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
HIT III 1996
Methods Patients n=123
Treatment n=63
Placebo n=60
Participants Inclusion
• tSAH on an initial CT scan
• within 12 hours after head injury
• 16-70 years
• 21 German Centres
Exclusions
gunshot wounds
Interventions • Nimodipine vs Placebo
• within 12 hours injury
• 2mg/hour intravenously, for 7- 10 days then
• orally 360mg/day to day 21.
Outcomes • Disability rating scale Barthel Index
• Glasgow outcome scale
• Presence of post- traumatic epilepsy
• 6 months follow up
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HIT III 1996 (Continued)
Notes • Reduced unfavourable outcome in Nimodipine group
• OR=0.34; 95% CI 0.15 to 0.76
• 2 lost to follow up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
HIT IV
Methods Patients n= 592 (525 ITT with definite diagnosis of tSAH) treatment n= 290
Placebo n= 287
13 countries participating, international.
Participants Inclusion
- tSAH on an initial CT scan
- within 12 hours after head injury
- 16-70 years
- start of treatment within 12 hours
- written consent
- at randomisation the patient had to have a GCS <15, unless patient was intubated
Exclusion:
- gunshot injury and penetrating head injury
- patients with non reacting pupils and no motor response for more than 1hr at time of entry to trial
- patients with low blood pressure <61/91
- co-existing pathology, e.g. cancer.
- patients who were likely to die within next 24 hours
- pregnancy
- known treatment by another investigational drug since injury
- previous enrolment to study
- impaired liver function.
Interventions Nimodipine
first dosage within 12 hours
Outcomes GOS at six months
Mortality
see HIT III
Notes
Risk of bias
Item Authors’ judgement Description
13Calcium channel blockers for acute traumatic brain injury (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
HIT IV (Continued)
Allocation concealment? Unclear B - Unclear
Sahuquillo 2000
Methods Patients n=22
Treatment n=11
Placebo n=11
Participants Moderate and severe traumatic brain injury, GCS <12 with mean Doppler flow velocity of >=100cm/
second within the first week. At least one hemisphere with suggested vasospasm
age 18-65 inclusive. Neuro ICU Spain
less than 7 days after trauma.
Exclusions: Brain death or predictable death within 72 hours of admission
Weight > 40 kg
Severe concomitant injury or disease
CPP < 60 mm Hg at randomization
No informed consent
Known medical history of intolerance to calcium channel blockers
Interventions Nicardipine
5 mg/hour for 7 days
Intravenous
As soon as possible after mean DFV > 100 cm/second
placebo: Same as treatment
Outcomes Death, morbidity, GOS.
Main variable assessed was the temporal evolution of the middle cerebral artery Doppler flow velocity
(DFV) at baseline and days 1, 3, 5 and 7. At least one hemisphere with suggested vasospasm was an
indication for inclusion
Notes Mean DFV dropped below 100 cm/second within 24 hours of treatment initiation in the treatment group
and within 72 hours in the control group
Mean time for recovery of elevated mean DFV was 3.33 days in the placebo group and 1.22 in the
nicardipine group (P=0.0039)
Nicardipine is effective in the reversal and prevention of increased mean DFV in patients with moderate
or severe head injury
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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D A T A A N D A N A L Y S E S
Comparison 1. Calcium channel blockers versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death (all-cause mortality) 5 1337 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.70, 1.16]
1.1 Nicardipine 2 46 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.20, 4.90]
1.2 Nimodipine 3 1291 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.70, 1.17]
2 Death and severe disability 5 1838 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.81, 1.18]
2.1 Nicardipine 1 22 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.25 [0.05, 1.27]
2.2 Nimodipine 4 1816 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.82, 1.20]
3 Adverse events 3 1324 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.15 [0.87, 1.52]
3.1 Nicardipine 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
3.2 Nimodipine 3 1324 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.15 [0.87, 1.52]
4 Hypotension 3 1324 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.74 [1.20, 2.52]
4.1 Nicardipine 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
4.2 Nimodipine 3 1324 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.74 [1.20, 2.52]
5 Mortality (by participant
subgroups)
4 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
5.1 tSAH 2 331 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.37, 0.94]
5.2 no tSAH 3 984 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.13 [0.83, 1.54]
6 Death and severe disability (by
participant subgroups)
3 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
6.1 tSAH 3 460 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.67 [0.46, 0.98]
6.2 no tSAH 2 831 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.77, 1.36]
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Analysis 1.1. Comparison 1 Calcium channel blockers versus control, Outcome 1 Death (all-cause
mortality).
Review: Calcium channel blockers for acute traumatic brain injury
Comparison: 1 Calcium channel blockers versus control
Outcome: 1 Death (all-cause mortality)
Study or subgroup Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nicardipine
Compton 1990 4/16 2/8 1.7 % 1.00 [ 0.15, 6.81 ]
Sahuquillo 2000 1/11 1/11 0.8 % 1.00 [ 0.06, 17.12 ]
Subtotal (95% CI) 27 19 2.5 % 1.00 [ 0.20, 4.90 ]
Total events: 5 (), 3 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Nimodipine
HIT I 1990 49/176 50/175 29.3 % 0.96 [ 0.61, 1.53 ]
HIT II 1994 90/405 98/414 59.5 % 0.92 [ 0.67, 1.28 ]
HIT III 1996 11/60 16/61 8.7 % 0.64 [ 0.27, 1.49 ]
Subtotal (95% CI) 641 650 97.5 % 0.90 [ 0.70, 1.17 ]
Total events: 150 (), 164 (Placebo)
Heterogeneity: Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 668 669 100.0 % 0.91 [ 0.70, 1.16 ]
Total events: 155 (), 167 (Placebo)
Heterogeneity: Chi2 = 0.75, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
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Analysis 1.2. Comparison 1 Calcium channel blockers versus control, Outcome 2 Death and severe
disability.
Review: Calcium channel blockers for acute traumatic brain injury
Comparison: 1 Calcium channel blockers versus control
Outcome: 2 Death and severe disability
Study or subgroup Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nicardipine
Sahuquillo 2000 3/11 7/11 1.3 % 0.25 [ 0.05, 1.27 ]
Subtotal (95% CI) 11 11 1.3 % 0.25 [ 0.05, 1.27 ]
Total events: 3 (), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
2 Nimodipine
HIT I 1990 82/176 89/175 20.4 % 0.84 [ 0.56, 1.28 ]
HIT II 1994 160/405 168/414 45.8 % 0.96 [ 0.72, 1.26 ]
HIT III 1996 15/60 28/61 6.5 % 0.40 [ 0.19, 0.85 ]
HIT IV 93/266 68/259 26.0 % 1.50 [ 1.04, 2.18 ]
Subtotal (95% CI) 907 909 98.7 % 0.99 [ 0.82, 1.20 ]
Total events: 350 (), 353 (Placebo)
Heterogeneity: Chi2 = 11.12, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 918 920 100.0 % 0.97 [ 0.81, 1.18 ]
Total events: 353 (), 360 (Placebo)
Heterogeneity: Chi2 = 13.85, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Chi2 = 2.73, df = 1 (P = 0.10), I2 =63%
0.1 0.2 0.5 1 2 5 10
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Analysis 1.3. Comparison 1 Calcium channel blockers versus control, Outcome 3 Adverse events.
Review: Calcium channel blockers for acute traumatic brain injury
Comparison: 1 Calcium channel blockers versus control
Outcome: 3 Adverse events
Study or subgroup Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nicardipine
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nimodipine
HIT I 1990 7/176 7/175 6.8 % 0.99 [ 0.34, 2.89 ]
HIT II 1994 122/423 113/429 85.8 % 1.13 [ 0.84, 1.53 ]
HIT III 1996 10/60 7/61 7.4 % 1.53 [ 0.55, 4.25 ]
Subtotal (95% CI) 659 665 100.0 % 1.15 [ 0.87, 1.52 ]
Total events: 139 (), 127 (Placebo)
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 659 665 100.0 % 1.15 [ 0.87, 1.52 ]
Total events: 139 (), 127 (Placebo)
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.4. Comparison 1 Calcium channel blockers versus control, Outcome 4 Hypotension.
Review: Calcium channel blockers for acute traumatic brain injury
Comparison: 1 Calcium channel blockers versus control
Outcome: 4 Hypotension
Study or subgroup Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nicardipine
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nimodipine
HIT I 1990 3/176 0/175 2.7 % 7.43 [ 0.77, 71.91 ]
HIT II 1994 71/423 47/429 91.4 % 1.63 [ 1.10, 2.40 ]
HIT III 1996 5/60 2/61 6.0 % 2.51 [ 0.55, 11.47 ]
Subtotal (95% CI) 659 665 100.0 % 1.74 [ 1.20, 2.52 ]
Total events: 79 (), 49 (Placebo)
Heterogeneity: Chi2 = 1.90, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Total (95% CI) 659 665 100.0 % 1.74 [ 1.20, 2.52 ]
Total events: 79 (), 49 (Placebo)
Heterogeneity: Chi2 = 1.90, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.5. Comparison 1 Calcium channel blockers versus control, Outcome 5 Mortality (by participant
subgroups).
Review: Calcium channel blockers for acute traumatic brain injury
Comparison: 1 Calcium channel blockers versus control
Outcome: 5 Mortality (by participant subgroups)
Study or subgroup Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 tSAH
HIT II 1994 31/96 52/114 70.3 % 0.57 [ 0.33, 1.00 ]
HIT III 1996 11/60 16/61 29.7 % 0.64 [ 0.27, 1.49 ]
Subtotal (95% CI) 156 175 100.0 % 0.59 [ 0.37, 0.94 ]
Total events: 42 (), 68 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
2 no tSAH
Compton 1990 4/16 2/8 2.6 % 1.00 [ 0.15, 6.81 ]
HIT I 1990 49/176 50/175 43.9 % 0.96 [ 0.61, 1.53 ]
HIT II 1994 59/309 46/300 53.6 % 1.30 [ 0.85, 1.98 ]
Subtotal (95% CI) 501 483 100.0 % 1.13 [ 0.83, 1.54 ]
Total events: 112 (), 98 (Placebo)
Heterogeneity: Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Chi2 = 5.22, df = 1 (P = 0.02), I2 =81%
0.1 0.2 0.5 1 2 5 10
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Analysis 1.6. Comparison 1 Calcium channel blockers versus control, Outcome 6 Death and severe
disability (by participant subgroups).
Review: Calcium channel blockers for acute traumatic brain injury
Comparison: 1 Calcium channel blockers versus control
Outcome: 6 Death and severe disability (by participant subgroups)
Study or subgroup Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 tSAH
HIT I 1990 26/35 25/36 13.5 % 1.27 [ 0.45, 3.54 ]
HIT II 1994 64/123 87/145 60.7 % 0.72 [ 0.45, 1.17 ]
HIT III 1996 15/60 28/61 25.8 % 0.40 [ 0.19, 0.85 ]
Subtotal (95% CI) 218 242 100.0 % 0.67 [ 0.46, 0.98 ]
Total events: 105 (), 140 (Placebo)
Heterogeneity: Chi2 = 3.35, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 2.07 (P = 0.038)
2 no tSAH
HIT I 1990 56/141 64/139 36.4 % 0.77 [ 0.48, 1.24 ]
HIT II 1994 96/282 81/269 63.6 % 1.20 [ 0.84, 1.71 ]
Subtotal (95% CI) 423 408 100.0 % 1.02 [ 0.77, 1.36 ]
Total events: 152 (), 145 (Placebo)
Heterogeneity: Chi2 = 2.09, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 3.02, df = 1 (P = 0.08), I2 =67%
0.1 0.2 0.5 1 2 5 10
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A P P E N D I C E S
Appendix 1. Search strategy
#1 explode “Calcium-Channel-Blockers” / all SUBHEADINGS
#2 ( ((calcium) near ((channel*) next (block* or inhibit* or antagonist*))) in TI ) or ( ((calcium) near ((channel*) next (block* or
inhibit* or antagonist*))) in AB )
#3 ( (verapimil* or nifedipine* or nicardipine* or amlodipine* or felodipine* or isradipine* or iacidipine* or nimodipine* or diltiazem*
) in TI )or( (verapimil* or nifedipine* or nicardipine* or amlodipine* or felodipine* or isradipine* or iacidipine* or nimodipine* or
diltiazem* ) in AB )
#4 #1 or #2 or #3
#5 explode “Brain-Injuries” / all SUBHEADINGS in MIME,MJME
#6 explode “Craniocerebral-Trauma” / all SUBHEADINGS in MIME,MJME
#7 explode “Subarachnoid-Hemorrhage” / all SUBHEADINGS in MIME,MJME
#8 ( ((head or crani* or capitis or brain* or forebrain* or skull* or hemisphere* or intracran* or orbit*) next (injur* or trauma* or
lesion* or damag* or wound* or destruction* or oedema* or edema* or fracture* or contusion* or commotion* or pressur*)) in TI ) or
( ((head or crani* or capitis or brain* or forebrain* or skull* or hemisphere* or intracran* or orbit*) next (injur* or trauma* or lesion*
or damag* or wound* or destruction* or oedema* or edema* or fracture* or contusion* or commotion* or pressur*)) in AB )
#9 (Subarachnoid near (hemorrhage or haemorrhage)) in TI ) or ( (Subarachnoid near (hemorrhage or haemorrhage)) in AB )
#10 #5 or #6 or #7 or #8 or #9
#11 #4 and #10
#12 #11 and Cochrane HSSS phases 1-2
WH A T ’ S N E W
Last assessed as up-to-date: 31 October 2005.
Date Event Description
7 June 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 1998
Review first published: Issue 3, 1998
Date Event Description
2 November 2005 New search has been performed The search was updated in November 2005, no new studies were identified
for inclusion
5 January 2002 New search has been performed New studies found and included or excluded.
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C O N T R I B U T I O N S O F A U T H O R S
JL contributed to the design of the protocol, searched for trials, extracted and entered data, contacted authors and wrote the paper. CG
contributed to protocol design, extracted data, gave statistical advice and helped to write the paper. GT contributed to the design of the
protocol, contacted authors of included trials and gave clinical input. KR contributed to the design of the protocol, attended steering
group meetings and helped to write the paper. DS attended steering group meetings, commented on the design of the protocol and
the paper.
D E C L A R A T I O N S O F I N T E R E S T
The individual views of members of the Steering Group regarding the clinical effectiveness and safety of calcium channel blockers,
together with any possible conflicts of interest, were recorded at the first Steering Group meeting before the start of the review.
Professor Teasdale, the principal investigator of study and a participant in study, believed that calcium channel blockers were clinically
effective in patients with tSAH but was not sure how clinically effective and felt that they were less useful, if at all useful, in patients
with acute traumatic brain injury.
Mr Shaw believed that calcium channel blockers were clinically effective in patients with spontaneous subarachnoid haemorrhage and
that there would probably be no effect in head-injured patients. However, there was a possibility that they might be of some benefit in
the subgroup of patients with tSAH.
Both Professor Teasdale and Mr Shaw have received funding from Bayer Pharmaceutical company, one of the producers of calcium
channel blockers. Both stated that there was no conflict of interest regarding the outcome of the review.
Dr Alderson, Dr Basnett, Professor Black, Miss Goldfrad, Ms Langham and Dr Rowan had no prior knowledge of the use of calcium
channel blockers and therefore had no prior views that might bias the review.
S O U R C E S O F S U P P O R T
Internal sources
• Intensive Care National Audit & Research Centre, UK.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Brain Injuries [complications; ∗drug therapy]; Calcium Channel Blockers [∗therapeutic use]; Randomized Controlled
Trials as Topic; Subarachnoid Hemorrhage [complications; ∗drug therapy]; Vasospasm, Intracranial [etiology; ∗prevention & control]
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MeSH check words
Humans
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